🔗 Visit the ClinicalTrials.gov page for NCT00420056
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Cyclin D as a therapeutic target in cancer. | Nat Rev Cancer | 2011 | 5.76 |
| 2 | Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. | Blood | 2012 | 2.37 |
| 3 | Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. | J Clin Invest | 2010 | 1.74 |
| 4 | Development of cell-cycle inhibitors for cancer therapy. | Curr Oncol | 2009 | 1.57 |
| 5 | Targeting CDK4 and CDK6: From Discovery to Therapy. | Cancer Discov | 2015 | 1.27 |
| 6 | Molecular targeted approaches in mantle cell lymphoma. | Semin Hematol | 2011 | 0.88 |
| 7 | Cyclin D1, cancer progression, and opportunities in cancer treatment. | J Mol Med (Berl) | 2016 | 0.76 |